Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C24H32N2O5.H2O4S |
Molecular Weight | 955.121 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@H](O)C3=CC(CCO)=C(O)C=C3)C=C1.CN(C)C(=O)COC4=CC5=C(CC[C@@H](C5)NC[C@H](O)C6=CC(CCO)=C(O)C=C6)C=C4
InChI
InChIKey=VPCOODFYDJWLHD-YMZXMBPUSA-N
InChI=1S/2C24H32N2O5.H2O4S/c2*1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h2*4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t2*20-,23-;/m00./s1
Molecular Formula | H2O4S |
Molecular Weight | 98.078 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C24H32N2O5 |
Molecular Weight | 428.5213 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Bedoradrine (also known as KUR-1246 or MN-221), an ultra selective beta 2-adrenoceptor agonist, that participated in phase II clinical trials as an adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy. In addition, the drug was involved in trials for the treatment of preterm labor in obstetrical practice. Bedoradrine is also was studied in phase I of clinical trials for its use for treating chronic obstructive pulmonary disease, however, the efficacy for this disease was uncertain.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19527375 |
Sample Use Guides
Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:38:03 GMT 2023
by
admin
on
Fri Dec 15 15:38:03 GMT 2023
|
Record UNII |
P875C0DV2V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000174949
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
194785-31-4
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
DTXSID40433338
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
DBSALT001988
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
P875C0DV2V
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
9963056
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
C77933
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
RR-91
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111083
Created by
admin on Fri Dec 15 15:38:03 GMT 2023 , Edited by admin on Fri Dec 15 15:38:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|